Medical Genetics Unit, University of Siena, Siena, Italy.
Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Cancer Res Treat. 2018 Apr;50(2):356-365. doi: 10.4143/crt.2017.125. Epub 2017 May 26.
Lung cancer is strongly associated to tobacco smoking. However, global statistics estimate that in females the proportion of lung cancer cases that is unrelated to tobacco smoking reaches fifty percent, making questionable the etiology of the disease.
A never-smoker female with primary EGFR/KRAS/ALK-negative squamous cell carcinoma of the lung and their normal sibswere subjected to a novel integrative "omic" approach using a pedigree-based model for discovering genetic factors leading to cancer in the absence of well-known environmental trigger. A first-stepwhole-exome sequencing on tumor and normal tissue did not identify mutations in known driver genes. Building on the idea of a germline oligogenic origin of lung cancer, we performed whole-exome sequencing of DNA from patients' peripheral blood and their unaffected sibs. Finally, RNA-sequencing analysis in tumoral and matched non-tumoral tissues was carried out in order to investigate the clonal profile and the pathogenic role of the identified variants.
Filtering for rare variants with Combined Annotation Dependent Depletion (CADD) > 25 and potentially damaging effect, we identified rare/private germline deleterious variants in 11 cancer-associated genes, none ofwhich, except one, sharedwith the healthy sib, pinpointing to a "private" oligogenic germline signature. Noteworthy, among these, two mutated genes, namely and , turned to be potential targets for therapy because related to known drivers, such as and .
In the era of precision medicine, this report emphasizes the importance of an "omic" approach to uncover oligogenic germline signature underlying cancer development and to identify suitable therapeutic targets as well.
肺癌与吸烟密切相关。然而,全球统计数据估计,在女性中,与吸烟无关的肺癌病例比例达到 50%,这使得该疾病的病因值得怀疑。
一位从未吸烟的女性,患有原发性 EGFR/KRAS/ALK 阴性鳞状细胞肺癌,其正常同胞接受了一种新颖的基于家系的“组学”方法,用于发现无已知环境诱因导致癌症的遗传因素。对肿瘤和正常组织进行的第一步全外显子组测序未发现已知驱动基因的突变。基于肺癌种系寡基因起源的观点,我们对患者外周血和未受影响的同胞的 DNA 进行了全外显子组测序。最后,对肿瘤和匹配的非肿瘤组织进行 RNA-seq 分析,以研究鉴定变异体的克隆特征和致病作用。
通过对具有 Combined Annotation Dependent Depletion (CADD) > 25 的罕见变异进行过滤,并具有潜在的破坏性影响,我们在 11 个癌症相关基因中鉴定出罕见/个体有害的种系变异,其中没有一个与健康同胞共享,而是指向一个“个体”寡基因种系特征。值得注意的是,在这些基因中,有两个突变基因,即 和 ,可能成为治疗的潜在靶点,因为它们与已知的驱动基因如 和 有关。
在精准医学时代,本报告强调了“组学”方法在揭示癌症发生的寡基因种系特征以及确定合适的治疗靶点方面的重要性。